Nanotechnology in Modern Cancer Therapy: A Comprehensive Review of Targeted Delivery, Gene Modulation, Tumor Microenvironment Engineering, and Clinical Progress

Abstract

Nanotechnology has emerged as a transformative approach in oncology, offering innovative strategies for cancer diagnosis, targeted drug delivery, imaging, and gene modulation. Nanocarriers including liposomes, polymeric micelles, dendrimers, nano emulsions, metal-based nanoparticles, and extracellular vesicles enable improved solubility, prolonged circulation, selective accumulation, and controlled release of anticancer agents. This review provides an in-depth analysis of tumour microenvironment responsive nanomaterials, passive and active targeting mechanisms, gene-delivery systems, hypoxia-targeted therapies, and nanotechnology-based methods to overcome multidrug resistance. Recent preclinical and clinical findings are summarized to highlight the translational promise of nano-oncology. Despite significant progress, biological variability, toxicity concerns, and regulatory challenges continue to limit widespread clinical adoption. Future directions emphasize personalized nanomedicine, AI-assisted nanoparticle design, theranostic platforms, and integration with immunotherapy. Overall, nanotechnology holds strong potential to reshape the future of cancer treatment by enabling more precise, effective, and minimally invasive therapeutic strategies.

Keywords

Introduction

Cancer therapy faces several inherent barriers that compromise the effectiveness of traditional treatments. One of the fundamental problems is the lack of therapeutic specificity, where conventional drugs are unable to clearly distinguish malignant cells from healthy tissues. This limitation results in widespread systemic damage and severe side effects. Many anticancer agents are also cleared rapidly from circulation, preventing them from remaining in the bloodstream long enough to reach therapeutic levels within tumors. As cancer progresses, tumor cells frequently acquire multidrug resistance, enabling them to survive repeated exposure to chemotherapeutic agents. Adding to these challenges is the heterogeneous nature of the tumor microenvironment, which varies significantly in structure, acidity, oxygen levels, and vascular features. Such inconsistencies restrict drug penetration and limit uniform responses to treatment. These long-standing issues highlight the need for advanced strategies such as nanotechnology to improve cancer therapy.

NANO-ONCOLOGY:

Nano-oncology encompasses several crucial applications that enhance how cancer is detected and treated. For early diagnosis, nanoscale tools including quantum dots, magnetic nanoparticles, PET-active particles, and radiolabeled nanoprobes allow high-precision visualization of tumors and biomarker identification. These technologies greatly increase diagnostic accuracy and enable earlier intervention.

In targeted therapy, nanomaterials can accumulate in tumor tissues either naturally through the enhanced permeability and retention effect or actively by attaching ligands that guide them to specific cancer receptors. Stimuli-sensitive nanoparticles further refine this accuracy by releasing their payload only in response to changes such as pH shifts or enzymatic activity within tumors.

Nano-enabled gene therapy is another transformative field, where nanoparticles deliver CRISPR-Cas9 constructs, siRNAs, miRNAs, and antisense molecules directly into cancer cells to repair or silence harmful genes.

Photothermal and photodynamic therapies benefit greatly from nanotechnology, using gold nanoshells, graphene oxide, or carbon nanotubes to convert light energy into heat or reactive oxygen species that destroy cancer cells selectively.

Nanotechnology also strengthens immunotherapy by enhancing antigen presentation, improving dendritic cell activation, and acting as carriers for immune checkpoint modulators. Through these combined innovations, nano-oncology offers highly targeted and less invasive cancer treatment options.

TUMOR MICROENVIRONMENT:

The tumor microenvironment has several distinguishing characteristics that influence how drugs behave after administration. Tumor blood vessels are often malformed and unusually permeable because of disorganized angiogenesis. This allows nanoparticles of suitable sizes to pass through large gaps in the vascular lining and enter tumor tissue.

In addition, tumors lack proper lymphatic drainage, so particles that enter the tumor tend to accumulate there instead of being washed away. This phenomenon is the foundation of the enhanced permeability and retention effect that underlies many nanoparticle-based therapies.

Hypoxia is another important component: tumors frequently have regions deprived of oxygen due to their rapid growth and inadequate blood supply. Low oxygen levels not only accelerate tumor progression but also reduce the effectiveness of many chemotherapeutic agents and encourage the development of drug resistance.

Tumor tissues also exhibit a distinctly acidic pH, ranging from 6.5 to 6.8, compared to normal physiological levels. Intracellular compartments such as lysosomes and endosomes are even more acidic. Nanocarriers engineered to respond to pH differences can use this property to release drugs directly in the tumor environment.

Furthermore, the tumor microenvironment contains elevated concentrations of enzymes like matrix metalloproteinases, which degrade extracellular matrix components. Nanoparticles designed with enzyme-responsive linkers can capitalize on this feature to release therapeutic molecules only when exposed to tumor-specific enzymes.

TARGETING STRATEGIES:

Passive targeting is based on the enhanced permeability and retention effect, whereby nanoparticles below a specific size range can spontaneously enter tumor tissues through gaps in the leaky vasculature. Techniques such as PEGylation extend circulation time and reduce immune detection, while optimizing nanoparticle size and surface characteristics improves their chances of reaching tumors. However, passive targeting is limited by patient-to-patient variations, shallow penetration into dense tumors, and the high fluid pressure within tumor masses that obstructs nanoparticle movement.

Active targeting offers a more refined approach by attaching ligands that recognize specific receptors overexpressed on cancer cells. Monoclonal antibodies such as trastuzumab, cetuximab, rituximab, and bevacizumab have successfully guided nanocarriers to HER2, EGFR, CD20, and VEGF receptors, respectively. Peptide ligands like RGD and NGR enhance targeting of integrins and CD13. Aptamers provide another route using engineered DNA or RNA sequences that bind with exceptional precision to tumor markers. Small molecules such as folic acid are widely used because many tumors overexpress folate receptors. By increasing cellular uptake and minimizing toxicity, these active targeting systems significantly enhance therapeutic precision.

TYPES OF NANOCARRIERS:

1. Liposomes

Liposomes consist of phospholipid bilayers surrounding an internal aqueous compartment, allowing them to encapsulate both water-soluble and fat-soluble medications. Their membrane-like structure mimics natural cells, providing excellent biocompatibility and reduced immune recognition. Clinically approved formulations such as Doxil and Onivyde demonstrate improved therapeutic performance and reduced organ toxicity compared with free chemotherapeutic drugs. Research continues to refine liposomes through ligand attachment, PEGylation, and pH-responsive designs to enhance targeting accuracy and control drug release.

2. Polymeric Micelles

Polymeric micelles form spontaneously when amphiphilic block copolymers assemble in water, producing a hydrophobic core that holds poorly soluble drugs such as paclitaxel. Their hydrophilic outer shell grants stability and prolonged circulation, while their small size enhances tumour penetration. These micelles have shown promising efficacy in breast cancer and have been adapted to deliver natural compounds such as luteolin with improved transdermal absorption.

3. Nano emulsions

Nano emulsions consist of nanosized oil droplets dispersed in water and stabilized by surfactants. Their tiny droplet size ensures excellent solubilization of hydrophobic drugs, improved absorption, and strong stability. Natural compound-based nano emulsions have demonstrated striking anticancer activity; for example, cinnamon oil nano emulsions show strong cytotoxic effects against lung cancer cells, while shiitake mushroom polysaccharide nano emulsions yield dramatically enhanced antitumor activity. Their ease of preparation further supports their growing use in oncology.

4. Dendrimers

Dendrimers are highly branched, tree-shaped macromolecules characterized by uniform size and an abundance of reactive surface groups. Their unique structure makes them highly suitable for transporting genetic materials such as siRNA and plasmids. Advanced dendrimers have been engineered to incorporate imaging agents, allowing simultaneous treatment and diagnostic tracking. Dendrimer-siRNA complexes show strong potential in suppressing genes linked to tumour growth and drug resistance.

5. Graphene & Graphene Oxide

Graphene-based nanomaterials possess exceptional surface area, optical behaviour, and photothermal conversion capacity. Graphene oxide (GO), with its functional groups and excellent dispersibility, serves as a versatile platform for drug loading and delivery. GO has shown remarkable results in photothermal therapy, where it can effectively ablate tumour tissue, and its ability to transport siRNA adds a genetic therapeutic dimension.

NANOTECHNOLOGY FOR GENE THERAPY:

Gene therapy represents one of the most promising applications of nanotechnology in oncology, particularly because many cancers arise from genetic mutations, dysregulated signaling pathways, or abnormal protein expression. Small interfering RNA (siRNA) and microRNA (miRNA) therapies can silence oncogenes or restore tumor suppressor gene activity, but their clinical use has been limited by instability, rapid degradation, and poor cellular uptake. Nanocarriers effectively overcome these barriers by shielding nucleic acids from enzymatic breakdown, enhancing circulation time, and facilitating transport across the cell membrane. Liposomes, dendrimers, and lipid nanoparticles have emerged as major delivery platforms because of their biocompatibility and ability to fuse with cell membranes. These nanocarriers ensure that genetic materials reach their intended intracellular targets, improving the overall efficiency of gene-silencing strategies.

CRISPR/Cas9 gene editing has further expanded therapeutic possibilities by allowing precise modifications to cancer-related genes. However, delivering CRISPR components—Cas9 protein and guide RNA—safely into mammalian cells remains challenging. Nanotechnology provides an effective solution by packaging CRISPR elements within lipid nanoparticles or polymeric systems that protect them from degradation and support their entry into the nucleus. Such platforms have demonstrated high gene-editing efficiency and the ability to suppress tumor growth in preclinical studies. As a result, nanotechnology-driven gene therapy is steadily advancing toward clinical application, with the potential to correct genetic errors directly at their source.

HYPOXIA-TARGETED NANOTHERAPY:

Hypoxia is a defining feature of solid tumors, resulting from uncontrolled cell proliferation and inadequate vascularization. The low oxygen environment drives tumor progression, increases metastatic potential, and contributes significantly to resistance against many chemotherapeutic drugs. Nanotechnology offers innovative strategies to exploit or overcome tumor hypoxia. For instance, nanoparticles carrying siRNA designed to silence hypoxia-inducible factor-1 (HIF-1) can effectively reduce the expression of this transcription factor, which plays a central role in angiogenesis and adaptive survival pathways. Other nanocarrier systems incorporate inhibitors such as HSP90 blockers, which indirectly diminish HIF-1 levels and sensitize cancer cells to therapy.

Hypoxia-responsive nanoparticles are engineered to release drugs only within oxygen-deficient regions, maximizing their cytotoxic effect while protecting healthy tissues. Some nanoparticles even carry oxygen-generating agents that locally replenish oxygen levels and improve the effectiveness of radiation or chemotherapy. Collectively, these hypoxia-targeted approaches have demonstrated significant tumor regression and increased drug sensitivity in laboratory and animal models.

MULTIDRUG RESISTANCE (MDR) REVERSAL:

Multidrug resistance remains one of the most formidable obstacles in cancer therapy, often arising from overexpression of efflux pumps that actively expel drugs from cancer cells. Nanotechnology helps overcome MDR by delivering chemotherapeutic agents through endocytosis, effectively bypassing drug-efflux mechanisms such as P-glycoprotein. Moreover, specific nanocarriers can directly inhibit these pumps; for example, nanoparticles functionalized with TPGS have shown the ability to suppress efflux activity and enhance intracellular drug retention.

Another important strategy involves the delivery of siRNA targeting genes responsible for MDR, such as MDR1. By reducing the expression of these resistance-associated proteins, nanoparticles restore the susceptibility of cancer cells to standard chemotherapy. Co-delivery systems that carry multiple drugs within a single nanocarrier provide synergistic effects, allowing for lower doses of each drug while preserving efficacy. Through this multifaceted approach, nanoparticles markedly improve treatment outcomes in resistant tumor models.

RECENT RESEARCH RESULTS:

Several recent studies have highlighted the therapeutic potential of nanotechnology in cancer treatment. For instance, paclitaxel nanoparticles modified with APRPG peptides have demonstrated significantly enhanced antitumor effects, achieving nearly 79% tumor inhibition compared with about 63% in their non-targeted counterparts, reflecting a statistically significant improvement. Nanoemulsions based on shiitake mushroom polysaccharides have shown an exceptional increase up to eighteenfold in anticancer activity, while maintaining structural stability over extended periods.

Dendrimer-based delivery systems combined with carbon dots have enabled concurrent imaging and drug delivery, with the added benefit of reversing multidrug resistance in breast cancer models. Gold nanorods used in photothermal therapy have produced striking results, with tumor regression rates reaching as high as 95% in preclinical studies. Additionally, CRISPR-loaded lipid nanoparticles have achieved gene-editing efficiencies between 80–90%, resulting in substantial induction of apoptosis. These findings collectively illustrate the transformative potential of nanotherapy.

CLINICAL TRIALS OF NANOMEDICINES:

Nanomedicine has progressed from laboratory research to clinical application, with several formulations already receiving approval for human use. Doxil, a liposomal form of doxorubicin, and Abraxane, an albumin-bound version of paclitaxel, represent major milestones in the integration of nanotechnology into oncology. These formulations have improved drug solubility, reduced toxicity, and strengthened therapeutic impact compared to conventional chemotherapy.

Beyond approved products, numerous nano therapies are currently undergoing various phases of clinical evaluation. CALAA-01, a targeted siRNA nanoparticle formulation, represents one of the earliest attempts to deliver RNA interference therapeutically in humans. BIND-014, a nanoparticle engineered to target prostate-specific membrane antigen, has shown promising early-phase results. NU-0129, a gold nanoparticle designed to deliver siRNA to brain tumours, is also advancing through clinical trials. These examples underscore the growing translation of nanotechnology from experimental platforms into clinically viable strategies.

LIMITATIONS OF NANOTECHNOLOGY:

Despite its promise, nanotechnology faces several significant limitations that affect its clinical translation. Biological challenges include rapid clearance by the immune system, limited ability to penetrate deeply into solid tumours, and considerable variation in patient response due to differences in vascular structure and tumour biology. Technical obstacles also persist, particularly in achieving consistent large-scale production of nanoparticles with uniform size, surface properties, and drug-loading efficiency.

Regulatory challenges arise from the absence of standardized guidelines for evaluating nano-formulations, leading to delays and uncertainties in approval processes. Additionally, concerns regarding long-term toxicity, biodegradability, and potential accumulation in vital organs require thorough investigation. These factors highlight the need for improved design strategies and more robust regulatory frameworks.

FUTURE PERSPECTIVES:

The future of nano-oncology is poised for rapid expansion as emerging technologies continue to shape the field. One promising direction is the use of artificial intelligence and machine learning to design nanoparticles with optimized size, charge, and targeting capabilities. Personalized nanomedicine, which tailors nanocarriers to the genetic and physiological profile of individual patients, represents another transformative advancement. Multifunctional nanoparticles capable of performing diagnosis, therapy, and monitoring simultaneously known as theranostic systems are gaining momentum.

Biodegradable and naturally derived nanomaterials may alleviate long-term toxicity concerns and facilitate safer clinical adoption. Additionally, incorporating nanotechnology into immunotherapy, such as nanoparticle-based vaccines and immune checkpoint modulators, may dramatically enhance anti-tumour immune responses. Looking ahead, the convergence of nanotechnology, immunology, genomics, and robotics could redefine the landscape of cancer treatment.

CONCLUSION

Nanotechnology has unlocked new opportunities in cancer therapy by addressing fundamental weaknesses in traditional treatment methods. Through enhanced targeting, improved drug stability, controlled release, and the ability to reverse drug resistance, nanocarriers significantly elevate therapeutic precision and reduce adverse effects. Although manufacturing challenges, biological variability, and regulatory uncertainties continue to hinder widespread clinical use, ongoing advancements are steadily overcoming these barriers. With continued innovation and rigorous research, nanotechnology is expected to become a central element of personalized and effective cancer treatment.

REFERENCES

1. Alkilany, A. M., Thompson, L. B., Boulos, S. P., Sisco, P. N., & Murphy, C. J. (2012). Gold nanorods: Their potential for photothermal therapeutics and drug delivery. Small, 8(3), 404–415. https://doi.org/10.1002/smll.201101706
2. Bazak, R., Houri, M., Achy, S. E., Hussein, W., & Refaat, T. (2014). Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Molecular and Clinical Oncology, 2(6), 904–908. https://doi.org/10.3892/mco.2014.356
3. Bazak, R., Houri, M., Hussein, W., & Refaat, T. (2015). Nanotechnology for the treatment of cancer. Cancer Nanotechnology, 6(1), 1–12. https://doi.org/10.1186/s12645-015-0011-x
4. Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014). Multifunctional nanoparticles for brain tumor imaging and therapy. Advanced Drug Delivery Reviews, 66, 42–57. https://doi.org/10.1016/j.addr.2013.10.015
5. Choi, K. Y., Liu, G., Lee, S., & Chen, X. (2012). Theranostic nanoplatforms for simultaneous cancer imaging and therapy: Current approaches and future perspectives. Nanoscale, 4(2), 330–342. https://doi.org/10.1039/c1nr11277e
6. Danhier, F. (2016). To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? Journal of Controlled Release, 244, 108–121. https://doi.org/10.1016/j.jconrel.2016.11.015
7. Davis, M. E., Chen, Z., & Shin, D. M. (2008). Nanoparticle therapeutics: An emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), 771–782. https://doi.org/10.1038/nrd2614
8. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16–20. https://doi.org/10.1021/nn900002m
9. Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 108, 25–38. https://doi.org/10.1016/j.addr.2016.04.025
10. Jiang, W., von Roemeling, C. A., & Chen, B. (2020). Design of nanocarriers for cancer therapy. Cancer Gene Therapy, 27, 278–291. https://doi.org/10.1038/s41417-019-0153-3
11. Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010). Nanomedicine. The New England Journal of Medicine, 363(25), 2434–2443. https://doi.org/10.1056/NEJMra0912273
12. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991–1003. https://doi.org/10.1038/nmat3776
13. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387
14. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108
15. Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014). Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie International Edition, 53(46), 12320–12364. https://doi.org/10.1002/anie.201403036
16. Tao, W., Zeng, X., Wu, J., Zhu, X., Yu, X., Zhang, X., & Han, J. (2020). Emerging two-dimensional monoelemental materials (Xenes) for biomedical applications. Chemical Society Reviews, 49(5), 1296–1316. https://doi.org/10.1039/C9CS00467A
17. Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012). Nanoparticle delivery of cancer drugs. Annual Review of Medicine, 63, 185–198. https://doi.org/10.1146/annurev-med-040210-162544
18. Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015). Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. Journal of Controlled Release, 200, 138–157. https://doi.org/10.1016/j.jconrel.2014.12.030
19. Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014). Non-viral vectors for gene-based therapy. Nature Reviews Genetics, 15(8), 541–555. https://doi.org/10.1038/nrg3763
20. Zheng, M., & Jiang, T. (2021). Nanotechnology-based strategies to overcome tumor hypoxia. Advanced Drug Delivery Reviews, 172, 1–18. https://doi.org/10.1016/j.addr.2021.03.002